This report provided an overview of several KIF5B-ALK fusion mutations with different breakpoints, including a case of advanced lung adenocarcinoma with KIF5B-ALK (K15:A20) fusion mutation that responded favorably to lorlatinib. This evidence concerns the gene ALK and lung adenocarcinoma.